KEY POINTS in the Treatment of Triple-Negative Breast Cancer (TNBC)
- When possible, the use of neoadjuvant therapy is preferred for the treatment of stage II to III TNBC.
- Enrollment in a clinical trial is suggested for patients with residual disease following neoadjuvant therapy.
- Genetic testing is recommended for all women with TNBC diagnosed under the age of 60 years.
- In patients with germline BRCA mutations, referral to a clinical trial that tests the role of poly (ADP-ribose) polymerase inhibitors and/or platinum agents is suggested.
- When possible, patients should be enrolled in a clinical trial using immune checkpoint inhibitors.
- Patients with metastatic TNBC should be considered for antibody-drug conjugate trials and molecularly targeted basket studies using relevant targeted drugs.